Table 1.
Patient characteristic.
| Characteristics | Value |
| Age----------year | |
| Mean | 56.6 |
| Median | 58 |
| Min–max | 18–80 |
| Sex----------n (%) | |
| Female | 74 (37%) |
| Male | 126 (63%) |
| OS----------days | |
| Mean | 357 |
| Median | 244 |
| Min–max | 19–2686 |
| PFS----------days | |
| Mean | 294 |
| Median | 204 |
| Min–max | 16–2686 |
| Tumour location----------n (%) | |
| Left | 93 (45%) |
| Right | 93 (47%) |
| Multifocal | 16 (8%) |
| Clinical Variable 1 | Value |
| Delay R 2----------days | |
| Mean | 415 |
| Median | 327 |
| Min–max | 23–2202 |
| Surgery---------- n (%) | |
| Yes | 143 (72%) |
| No | 57 (28%) |
| Symptoms---------- n (%) | |
| Yes | 164 (78%) |
| No | 44 (22%) |
| Neurological deficit---------- n (%) | |
| Yes | 68 (34%) |
| No | 132 (66%) |
| Epilepsy---------- n (%) | |
| Yes | 26 (13%) |
| No | 174 (87%) |
| Intracranial hypertension ---------- n (%) | |
| Yes | 41 (21%) |
| No | 159 (79%) |
| Haematological toxicity---------- n (%) | |
| Yes | 48 (24%) |
| No | 152 (76%) |
1 Patient data retrieved from clinical examination at the start of the bevacizumab treatment. 2 Delay between GBM diagnosis and start of bevacizumab treatment.